Evidence from clinical trials established the efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). Here, VEGFA is linked to macular retinal edema.